Hackensack Meridian Well being introduced it launched a most cancers threat and early detection program on the well being system’s Hennessy Institute for Most cancers Prevention and Utilized Molecular Drugs in partnership with oncology-focused precision-health know-how firm CancerIQ, aimed toward bettering early analysis, remedy and prevention.
This system integrates superior know-how, genomics and AI into real-time digital well being document (EHR) workflows to streamline complete most cancers threat assessments and customized care plans.
The HMH program features a CancerIQ device that collects private and household medical histories and way of life elements to determine people with a better most cancers threat.
Sufferers recognized as high-risk are supplied with customized early detection and prevention methods.
This system additionally leverages molecular most cancers screening strategies, equivalent to liquid biopsies, to detect most cancers at its earliest levels by figuring out genetic supplies launched into the bloodstream.
“This new program opens a complete new area in most cancers, from stopping most cancers in somebody with genetic threat elements to detecting most cancers earlier and decreasing most cancers recurrence,” Andre Goy, chairman and govt director of John Theurer Most cancers Heart, mentioned in an announcement.
The initiative is a part of HMH’s Hennessy Institute for Most cancers Prevention and Utilized Molecular Drugs (HICAP) and will likely be supplied on the newly established Most cancers Heart at Totowa, N.J., with plans to increase to Clifton, N.J., in early 2025.
THE LARGER TREND
The World Well being Group estimates that between 30% to 50% of all most cancers instances are preventable and improved entry to genetic testing helps display, check and determine extra individuals who could also be in danger.
In a January interview with MobiHealthNews, Feyi Ayodele, founder and CEO of CancerIQ, described the advantages of customized care plans and superior applied sciences to assist suppliers detect most cancers early.
“The extra we be taught concerning the relationship between most cancers and our genes and different elements because the science evolves, we should always be capable to act on that data. Basically, what we do is we make it in order that your on a regular basis supplier can use that info and design a customized care plan,” Ayodele mentioned.
Most cancers IQ secured $14 million in Collection B funding in 2020, two years after elevating $4.8 million in Collection A financing.
On Thursday, the Chicago-based firm introduced it secured progress funding from Decathlon Capital Companions, nevertheless it didn’t make the quantity raised public.
Different firms within the precision oncology area embody GE HealthCare and BAMF Well being, which lately partnered to bolster the adoption of theranostics.
Theranostics combines diagnostic imaging and focused remedy to allow customized remedy by figuring out and straight treating most cancers cells.
